Dr Paul Lorigan is a Reader in Medical oncology at the University of Manchester and Honorary Consultant Medical Oncologist at the Christie NHS Foundation Trust.
Dr Lorigan leads a research based clinical team, specialising in developing new treatments for malignant melanoma.
Dr Lorigan is Chair Elect of Melanoma Focus, the UK national charity dedicated to research, treatment, education and information for clinical teams treating melanoma patients, for patients and their families. He chaired the UK NCRI Melanoma Clinical Studies Group from 2006 to 2012, and is a member of the EORTC Melanoma Group.
He is principal investigator on a number of international clinical trials. The Manchester group, a collective of researchers and academics, are international leaders in research and treatment of melanoma. Manchester is the only centre in the UK able to deliver Adoptive Cell Therapy for melanoma, and only one of three in Europe. Dr Lorigan leads the clinical team that works closely with these groups, developing a model of personalised medicine in melanoma. This also allows a link between research in targeted therapy and immunotherapy, which greatly strengthens the centre's research output and competitive ability with the other five to six main centres leading internationally in this area.
Paul Lorigan has been involved in a number of other projects. He was expert advisor to NICE in the Single Technology Appraisals (STA) of both ipilimumab and vemurafenib, is an advisor to Factor 50, and is a member of the Melanoma Forum. He also acts in the advisory capacity to many national and international groups. He is principal investigator on a number of international studies in this area and has been a co-author on many of the definitive studies in the last 10 years. Dr Lorigan has published over 100 peer reviewed papers.
Professor Juan Valle is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Prof Valle is an Honorary Professor in the Manchester Academic Health Sciences Centre (School of Cancer and Enabling Sciences). He is based in the department of Medical Oncology at The Christie within the gastrointestinal disease group and treats cancers of the pancreas, liver and biliary tract and neuroendocrine tumours. He is the Lead Clinician of The Christie’s Neuroendocrine Tumour service, awarded European Centre of Excellence status in March 2011.
Prof Valle is a member of the UK National Cancer Research Network (NCRN) upper gastrointestinal clinical studies group and a co-founding member of its cholangiocarcinoma working party. He also sits on the NCRN pancreatic cancer and hepatobiliary subgroups and chairs the Neuroendocrine subgroup. He has been awarded a number of grants for research leading to numerous publications and presentations, as well as national and international meetings, and he is a peer reviewer for a number of international medical journals. Prof Valle is a member of ASCO (American Society of Clinical Oncology), ESMO (European Society of Medical Oncology), UKI NETS (UK and Ireland Neuroendocrine Tumour Society) and ENETS (European Neuroendocrine Tumour Society).
Dr Andrew Clamp is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Dr Clamp qualified in medicine by gaining a first class honours degree from the University of Cambridge and then subsequently completed his clinical training (BMBCh) at the University of Oxford in 1996. His specialist training in Medical Oncology has taken place in Manchester at the Christie Hospital.
During his training in Manchester he gained extensive experience in the design and running of clinical trials, particularly in ovarian cancer. He was awarded a PhD for work in the laboratory of Professor John Gallagher determining the role of heparan sulphate in determining the bioactivity of collagen- XVIII derived endostatin, a key endogenous anti-angiogenic protein.
Dr Clamp is a Clinical Senior Lecturer and Women's Cancer Centre Lead for the Institute of Cancer Sciences, University of Manchester and has an Honorary Consultant Appointment in Medical Oncology at The Christie NHS Foundation Trust, Manchester. He sits on the National Cancer Research Institute Gynaecological Cancers Clinical Studies Group and both the ovarian and endometrial subgroups. Dr Clamp is also a Member of UCL Cancer Trials Unit Trials Steering Committee, and a member of the Scottish Gynaecological Cancers Clinical Trials Group.
Dr Clamp teaches regularly on the undergraduate medical course at the University of Manchester and as part of the MRes Oncology Programme. He has been invited to give several national/ international teaching lectures including 'Incorporating Anti-vascular therapy into the Management of Ovarian Cancer' at the European Cancer Congress in Amsterdam in October 2013.
Dr Alison Birtle is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre, Preston.
Dr Birtle’s specialist interests cover chemotherapy for urological tumours, targeted therapy and radiotherapy developments. She trained in London at Charing Cross and Westminister Medical School and as a specialist registrar in clinical oncology in North Thames. She completed her MD Thesis at the Institute of Urology, University College London, in PSA negative prostate cancer and finished site specialised training at the Academic Urology Unit, Royal Marsden Hospital.
In November 2007, Dr Birtle was appointed ‘Honorary Clinical Senior Lecturer’ at The University of Manchester in recognition of her academic and clinical research of cancer.
She was Clinical Lead for Research for Lancs & South Cumbria Cancer Research Network until April 2014 and is a member of the Research and innovation Committee at Lancs Teaching Hospitals NHS Foundation Trust and an active member of the Cancer Research Partnership Group.
Dr Birtle is committee member of the British Uro-Oncology Group and Trustee of the Action on Bladder cancer.
Ms Zahida Saad is a Consultant Breast Surgeon based at Manchester Foundation Trust, South Manchester
Ms Saad trained in breast surgery in Guys Hospital, London and completed Specialist training in London Regional Cancer Centre/ University of Ontario, Ontario, Canada. She originally took the post of Consultant Breast Surgeon in Edinburgh Breast Unit for over a year and after this has been a Consultant Breast Surgeon at Salford Royal NHS Foundation Trust since 1996.
Ms Saad is a member of the British Association of Surgical Oncologists (Breast Subgroup) and the Medical Protection Society.
Dr Was Mansoor is a Consultant Medical Oncologist at The Christie NHS Foundation Trust in Manchester. He is cuurently the Clinical Director of Medical Oncology at The Christie.
Dr Mansoor moved to Manchester in 1998 to take up his career in Medical Oncology. During his training, he researched the relationship between cancer (in particular upper GI cancers) and the immune system and attained a PhD based on this research. Dr Mansoor continued his service and research interests into upper GI cancers, neuroendocrine cancers and other rare cancers when he became a consultant at The Christie in 2006. He also has an interest in developing medical education and became the Training Programme Director for Medical Oncology in 2009 to develop medical education.
Dr Mansoor is now the head of the oesphagogastric department, where he and his team provide a specialised service to patients, incorporating access to many cutting edge trials.
Dr Mansoor speaks English, Urdu and Punjabi.
Dr Vivek Misra is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Dr Misra has been a consultant at The Christie since 2005. He is a member of the breast and gastrointestinal disease groups and is an investigator for several national and international clinical trials. Dr Misra treats his patients with chemotherapy, hormone therapy, biological therapy and radiotherapy.
Mr Vijay Ramani is a Consultant Urological Surgeon based at The Christie NHS Foundation Trust in Manchester.
From 1999 Mr Ramani has been appointed as a Consultant Urological Surgeon at University Hospital South Manchester and The Christie.
His speciality interest is in prostate, bladder, renal, testis and complex pelvic and retroperitoneal cancers. He is a member of the Northwest Robotic Group and has also been responsible for the introduction and advancement of robotic surgery at The Christie and regularly undertakes robot assisted laparoscopic prostatectomy on patients with localised adenocarcinoma prostate.
Mr Ramani's other specialist operations including radical cystectomy and neobladder reconstruction, partial nephrectomy for small renal tumours, radical nephrectomy and complex inferior vena cava surgery. Mr Ramani also undertakes surgery for testis cancer including primary orchidectomy and retroperitoneal lymph node dissection.
He is currently the Clinical Lead for Urology at University Hospital South Manchester and a Lecturer of the European School of Urology. He has given lectures both regional, nationally and internationally on Urological cancers and regularly recruits patients to trials through the specialist MDT set up. He also consults on the prostate and issues surrounding men’s health.
Professor Tim Illidge is a Consultant Clinical Oncologist based at The Christie NHS Foundation Trust.
Prof Illidge completed an undergraduate degree at London University and received his medical degree from Guy's Hospital Medical School, London, and subsequently his PhD from the Univ. of Southampton. After completing his training in medicine and oncology he was awarded a US Senior Fullbright Fellowship & UK Winston Churchill Fellowship, which enabled him to work as part of the lymphoma team at Stanford University, California.
Mr Sumohan Chatterjee is a Consultant Breast Surgeon based at Manchester Foundation Trust, South Manchester.
After working as a Research Fellow at the Academic Surgical Unit in Hull University, Mr Chatterjee was appointed as a Higher Surgical Trainee in the North West Deanery. Mr Chatterjee undertook specialist training in breast surgery at Bolton Hospital and South Manchester University Hospital.
Later Mr Chatterjee was appointed to the prestigious National Fellowship in oncoplastic breast surgery in Sheffield where he worked with the plastic surgery team with the emphasis of training on breast reconstruction and cosmetic breast surgery.
After initially working as a consultant at Stepping Hill Hospital (under the new consultant entry scheme) in 2004 he moved to the substantive post of Consultant Oncoplastic Breast Surgeon at Salford Royal Foundation NHS Trust in April 2005.
He offers modern reconstructive techniques using Strattice and TiLOOP and specialises in drain free mastectomy.